PI
Pfizer Inc
ContrarianQuality / disciplined sizing
Total reported value
$238.8M
Reporting period: 2026-03-31 · Number of holdings: 21
Pfizer Inc disclosed 21 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $238.8M and a quarterly turnover rate of 31.1%.
Personality snowflake
- Concentration
- 60.72
- Portfolio Stability
- 31.1
- Momentum/Contrarian
- 0
- Sector conviction
- 0
- Diversification
- 36
- Sizing Uniformity
- 86.46
Recent moves
Trim WVE
0.0% -$19.9M
Add ALLO
0.0% $19.6M
Add ORIC
-11.1% $13.7M
Trim ARVN
0.0% -$6.1M
Trim CELC
-15.4% -$3.5M
Trim CRDF
0.0% -$3.0M
Holdings Map
New buyAddUnchangedTrim
Top 10 holdings by weight
Full holdings list this quarter
Showing top 18 holdings (of 21 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ORIC | Oric Pharmaceuticals INC | Stock-Other | 24.14% | +5.54% | -11.08% | |
| 2 | ALLO | Allogene Therapeutics INC | Stock-Other | 20.85% | +8.09% | — | |
| 3 | ARVN | Arvinas INC | Stock-Other | 14.63% | -2.71% | — | |
| 4 | CELC | Celcuity INC | Stock-Other | 13.13% | -1.61% | -15.38% | |
| 5 | ✓ | Zura Bio LTD | Stock-Other | 7.05% | +0.47% | -4.41% | |
| 6 | WVE | Wave Life Sciences Ltd. | Stock-Other | 5.00% | -8.48% | — | |
| 7 | PYXS | Pyxis Oncology INC | Stock-Other | 3.86% | +0.44% | — | |
| 8 | CRBU | Caribou Biosciences INC | Stock-Other | 3.50% | +0.35% | — | |
| 9 | SPRO | Spero Therapeutics INC | Stock-Other | 2.31% | -0.02% | — | |
| 10 | BHVN | Biohaven Ltd. | Stock-Other | 1.77% | -0.64% | — | |
| 11 | CRDF | Cardiff Oncology INC | Stock-Other | 1.57% | -1.30% | — | |
| 12 | ZNTL | Zentalis Pharmaceuticals INC | Stock-Other | 0.84% | +0.30% | — | |
| 13 | NXTC | Nextcure INC | Stock-Other | 0.64% | -0.31% | -2.72% | |
| 14 | AGMB | Agomab Therapeutics NV | Stock-Other | 0.34% | +0.34% | NEW | |
| 15 | QTTB | Q32 Bio INC | Stock-Other | 0.31% | -0.08% | -63.42% | |
| 16 | BOLT | Bolt Biotherapeutics INC | Stock-Other | 0.06% | -0.01% | — | |
| 17 | DNA | Ginkgo Bioworks Holdings INC | Stock-Other | 0.01% | — | — | |
| 18 | SENS1GBP | Senseonics Holdings INC | Stock-Other | 0.01% | — | — |
Reported value over time
Sector allocation
Not enough sector-mapped data yet
Sector allocation over time
Quarterly history
Holding changes this quarter
Pfizer Inc's most significant position changes for 2026-03-31: Sold out: An2 Therapeutics INC (ANTX); New buy: Agomab Therapeutics NV (AGMB); Trim: Oric Pharmaceuticals INC (ORIC) — shares -11.08%; Trim: Celcuity INC (CELC) — shares -15.38%; Trim: Zura Bio LTD — shares -4.41%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ALLO | Allogene Therapeutics INC | +8.1% | — | Unchanged |
| 2 | ORIC | Oric Pharmaceuticals INC | +5.5% | -11.08% | Trim |
| 3 | ✓ | Zura Bio LTD | +0.5% | -4.41% | Trim |
| 4 | PYXS | Pyxis Oncology INC | +0.4% | — | Unchanged |
| 5 | CRBU | Caribou Biosciences INC | +0.4% | — | Unchanged |
| 6 | ZNTL | Zentalis Pharmaceuticals INC | +0.3% | — | Unchanged |
| 7 | DNA | Ginkgo Bioworks Holdings INC | — | — | Unchanged |
| 8 | SENS1GBP | Senseonics Holdings INC | — | — | Unchanged |
| 9 | BOLT | Bolt Biotherapeutics INC | 0% | — | Unchanged |
| 10 | SPRO | Spero Therapeutics INC | 0% | — | Unchanged |
| 11 | QTTB | Q32 Bio INC | -0.1% | -63.42% | Trim |
| 12 | NXTC | Nextcure INC | -0.3% | -2.72% | Trim |
| 13 | BHVN | Biohaven Ltd. | -0.6% | — | Unchanged |
| 14 | CRDF | Cardiff Oncology INC | -1.3% | — | Unchanged |
| 15 | CELC | Celcuity INC | -1.6% | -15.38% | Trim |
| 16 | ARVN | Arvinas INC | -2.7% | — | Unchanged |
| 17 | WVE | Wave Life Sciences Ltd. | -8.5% | — | Unchanged |
| 18 | ANTX | An2 Therapeutics INC | — | EXIT | Sold out |
| 19 | AGMB | Agomab Therapeutics NV | — | NEW | New buy |
FAQ
What is Pfizer Inc and what type of investor is it?
Pfizer Inc is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2026-03-31), the firm manages a tracked equity portfolio valued at approximately $238.8M, spread across 21 disclosed positions.
What are Pfizer Inc's largest equity positions?
Based on the latest 13F filing, Pfizer Inc's top holdings by market value are:
1. Oric Pharmaceuticals INC (ORIC) — $57.7M (24.1%)
2. Allogene Therapeutics INC (ALLO) — $49.8M (20.9%)
3. Arvinas INC (ARVN) — $34.9M (14.6%)
4. Celcuity INC (CELC) — $31.3M (13.1%)
5. Zura Bio LTD — $16.8M (7.0%)
What changes did Pfizer Inc make in its most recent portfolio filing?
In the latest reported quarter, Pfizer Inc made 7 notable position adjustments: 1 new positions were initiated, 0 existing holdings were added to, 5 positions were partially reduced, and 1 were completely exited. The largest of these moves: Sold out: An2 Therapeutics INC (ANTX); New buy: Agomab Therapeutics NV (AGMB); Trim: Oric Pharmaceuticals INC (ORIC) — shares -11.08%; Trim: Celcuity INC (CELC) — shares -15.38%; Trim: Zura Bio LTD — shares -4.41%
What sectors does Pfizer Inc focus on?
Sector breakdown data is not yet available for Pfizer Inc. Check back after the next 13F processing cycle.